Skip to main content
This site provides educational information only, not medical advice. Always consult a qualified healthcare provider.
Cornerstone Guide~25 min read

The Ultimate Guide to Hidradenitis Suppurativa

Everything you need to know about HS, from understanding what it is and why it happens, to every treatment option available, lifestyle strategies, surgery, and the latest research. Written for patients, by people who care.

What Is Hidradenitis Suppurativa?

Hidradenitis suppurativa (pronounced hid-rad-en-EYE-tis sup-yoo-ruh-TIE-vuh), also known as HS or acne inversa, is a chronic inflammatory skin disease that causes painful lumps, abscesses, and tunnels to form deep in the skin. It primarily affects areas where skin rubs against skin, the armpits, groin, inner thighs, buttocks, and under the breasts.

HS is not contagious, not caused by poor hygiene, and not simply "bad acne." It is a systemic inflammatory condition driven by immune system dysfunction, with the skin as the primary site of visible disease. The condition was first described in medical literature in the 1800s, yet it remains significantly underdiagnosed and undertreated today.

Key Facts About HS

Prevalence
1–4% of population
Average diagnosis delay
7–10 years
Gender ratio
3:1 female to male
Onset age
Usually 20s–30s
Associated conditions
IBD, arthritis, metabolic syndrome
FDA-approved biologics
3 (as of 2024)

This guide is for educational purposes. Always consult a board-certified dermatologist for diagnosis and personalized treatment.

Causes and Risk Factors

HS develops from a complex interplay of genetic predisposition, immune system dysfunction, and environmental triggers. Understanding the causes helps explain why HS behaves the way it does, and why certain treatments work.

The Biological Mechanism

The disease begins with follicular occlusion, the hair follicle becomes blocked, trapping keratin and bacteria. This triggers an intense inflammatory response that ruptures the follicle, spreading inflammation into the surrounding tissue. The immune system then mounts an exaggerated response, involving cytokines like TNF-alpha, IL-1, IL-17, and IL-23, which drive the chronic inflammation characteristic of HS.

Risk Factors

Risk FactorImpactNotes
Family historyHigh~40% of patients have an affected relative; several gene mutations identified
Female sexHigh3x more common in women; hormonal factors play a significant role
SmokingHighSmokers have more severe disease; nicotine affects follicular keratinocytes
Obesity/overweightHighMechanical friction + metabolic inflammation; weight loss can improve symptoms
African descentModerate–HighHigher prevalence and often more severe presentation
Metabolic syndromeModerateInsulin resistance, diabetes, and PCOS are associated with HS

Symptoms and Diagnosis

HS produces a characteristic set of symptoms that, when recognized together, distinguish it from other skin conditions. The hallmarks are recurrence in the same locations, formation of sinus tracts, and progressive scarring.

Diagnosis is clinical, based on history and physical examination. There is no blood test or biopsy that definitively diagnoses HS. The diagnostic criteria require: (1) typical lesions (nodules, abscesses, sinus tracts, scars), (2) typical locations (axillae, groin, perineum, inframammary), and (3) recurrence (at least 2 episodes in 6 months).

For a detailed breakdown of every HS symptom, see our HS Symptoms Guide. For visual descriptions of what HS looks like, see What Does HS Look Like?

HS Stages (Hurley Classification)

HS severity is classified using the Hurley Staging System into three stages. Your stage guides treatment decisions and helps track disease progression.

I

Isolated abscesses, no sinus tracts, minimal scarring. Responds to topical and oral treatments.

II

Recurrent abscesses with sinus tracts and scarring. Requires systemic treatment, often biologics.

III

Diffuse disease with extensive tunnels and scarring. Requires biologics and often surgery.

For the complete stages guide with treatment recommendations, see Hidradenitis Suppurativa Stages.

Treatment Options

HS treatment has advanced dramatically in recent years. The current approach is multimodal, combining medical therapy, lifestyle modification, and in some cases surgery. Treatment is always individualized based on disease stage, severity, and patient response.

1
Topical Treatments: Clindamycin 1% solution, resorcinol cream. Best for Stage I and as adjuncts in higher stages.
2
Oral Antibiotics: Doxycycline, minocycline, clindamycin + rifampicin. Used for moderate disease and acute flares.
3
Hormonal Therapy: Spironolactone, oral contraceptives (women). Particularly effective for hormonally-driven disease.
4
Biologic Therapy: Adalimumab (Humira), secukinumab (Cosentyx), bimekizumab (Bimzelx). FDA-approved for moderate-to-severe HS.
5
Surgery: Deroofing, wide local excision, CO2 laser. For sinus tracts and severe localized disease.

For a complete treatment guide including flare management protocols, see HS Flare Treatment and our How to Manage HS Flares guide.

Lifestyle Management

Lifestyle modifications are a critical complement to medical treatment. While they cannot replace medication, they can meaningfully reduce flare frequency and severity.

Diet

Reduce dairy and high-glycemic foods; emphasize anti-inflammatory eating

Smoking Cessation

Smoking is one of the strongest modifiable HS risk factors; cessation often improves disease activity

Weight Management

Even modest weight loss can reduce friction, improve metabolic factors, and decrease flare frequency

Stress Management

Psychological stress is a documented HS trigger; mindfulness and therapy can help

Clothing Choices

Loose, breathable fabrics reduce friction and sweating, key HS triggers

Wound Care

Proper daily wound care prevents secondary infection and reduces odor

Mental Health and HS

The psychological burden of HS is profound and often underestimated. Studies consistently show that HS has a greater impact on quality of life than many other chronic skin conditions, including psoriasis. Depression affects up to 40% of HS patients, and anxiety is similarly prevalent.

Mental health support should be considered an essential component of HS care, not an optional add-on. Cognitive behavioral therapy (CBT), mindfulness-based stress reduction, and peer support groups have all shown benefit for chronic illness patients.

If you are struggling

You are not alone. The HS community is large, supportive, and understands what you are going through in a way that people without HS simply cannot.

Surgery for HS

Surgery is an important tool in the HS treatment arsenal, particularly for patients with established sinus tracts and scarring that do not respond adequately to medical therapy. The goal of surgery is to remove affected tissue, eliminate tunnels, and provide long-term relief.

The main surgical options range from simple deroofing (removing the roof of a sinus tract) to wide local excision (removing all affected tissue in a region). Surgery is most effective when combined with ongoing biologic therapy to prevent recurrence in new areas.

For a complete guide to HS surgery and recovery, see our HS Surgery Patient Guide and HS Surgery Recovery page.

Research and Future Treatments

HS research has accelerated dramatically in the past decade. The approval of adalimumab in 2015 opened the door to a new era of biologic treatments, and several additional biologics have since been approved or are in late-stage clinical trials.

Current areas of active research include: new biologic targets (IL-36, JAK inhibitors), combination therapy approaches, biomarkers for treatment response prediction, and the role of the skin microbiome in HS. The pipeline for new HS treatments has never been more robust.

For the latest research updates, visit our Research page and the HS Research Updates blog.

Frequently Asked Questions

What is hidradenitis suppurativa?
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that causes painful nodules, abscesses, and sinus tracts (tunnels) to form in areas where skin rubs together, most commonly the armpits, groin, buttocks, and under the breasts. It is driven by immune system dysfunction and follicular occlusion, not poor hygiene or infection.
How common is hidradenitis suppurativa?
HS affects approximately 1–4% of the global population, making it more common than many people realize. It disproportionately affects women (3:1 female-to-male ratio), people of African descent, and people with obesity or metabolic syndrome. Despite its prevalence, it remains significantly underdiagnosed.
Is hidradenitis suppurativa curable?
There is currently no cure for HS. However, it is a manageable condition. With the right combination of medical treatment, lifestyle modifications, and in some cases surgery, many patients achieve significant reduction in disease activity and improved quality of life. Some patients achieve long-term remission.
What causes hidradenitis suppurativa?
The exact cause of HS is not fully understood, but it involves a combination of factors: follicular occlusion (hair follicles becoming blocked), immune system dysregulation (particularly the IL-1, TNF-alpha, and IL-17 pathways), genetic predisposition (approximately 40% of patients have a family history), and environmental triggers (smoking, obesity, hormonal factors, friction).
When should I see a doctor for HS?
See a dermatologist if you have recurring painful lumps in skin-fold areas, lesions that drain and leave scars, multiple simultaneous lesions, or symptoms that have persisted for more than 3 months. Early diagnosis and treatment are critical for preventing disease progression and permanent scarring.

Stay Updated on HS

New research, treatment updates, and community support, in your inbox monthly.

No spam, ever. Unsubscribe anytime.

Medical References

  1. [1]Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. PubMed
  2. [2]Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. PubMed
  3. [3]Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(1):76-90. PubMed
  4. [4]Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. PubMed
  5. [5]Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. PubMed